Tiglutik is a prescription medication developed specifically for individuals with amyotrophic lateral sclerosis (ALS) who have difficulty swallowing. It is the only formulation of riluzole approved for both oral and PEG tube administration, providing options for patients with different needs. Tiglutik is taken twice a day and is equivalent to one RILUTEK tablet, offering convenience and flexibility for ALS patients throughout all stages of the disease.
Tiglutik is designed to meet the unique needs of individuals with ALS, providing a mildly thick liquid formulation that can be easily administered. It helps manage the symptoms of ALS and has been approved for use from the time of diagnosis. With its focus on patient support and resources, Tiglutik aims to assist individuals with ALS in accessing the medication they need for their treatment journey.
Generated from the website